STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Zoetis Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zoetis Inc. (ZTS) furnished an update on its business by reporting third-quarter 2025 results and full-year 2025 guidance. The company announced these details in a press release dated November 4, 2025, which is provided as Exhibit 99.1.

The disclosure is presented under Item 2.02: Results of Operations and Financial Condition and is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not incorporated by reference unless specifically stated. The filing confirms Zoetis’ common stock trades on the NYSE under the symbol ZTS.

Positive
  • None.
Negative
  • None.
0001555280false00015552802025-11-042025-11-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 4, 2025
Zoetis Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3579746-0696167
(State or other jurisdiction(Commission File(I.R.S. Employer
of incorporation)Number)Identification No.)
10 Sylvan Way
Parsippany
New Jersey
07054
(Address of principal executive offices)(Zip Code)

(973) 822-7000
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareZTSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

                                     Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.








Item 2.02 Results of Operations and Financial Condition

On November 4, 2025, Zoetis Inc. (the Company) issued a press release reporting its financial results for the third quarter of 2025 and its guidance for full year 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits

(d)    Exhibits
Exhibit No.Description
99.1
Press Release of Zoetis Inc. dated November 4, 2025, reporting Zoetis' financial results for the  
third quarter of 2025 and its guidance for full year 2025.
EX-101.INSInline XBRL INSTANCE DOCUMENT
EX-101.SCHInline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
EX-101.CALInline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.LABInline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PREInline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
EX-101.DEFInline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)





SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
Zoetis Inc.
November 4, 2025
By:/S/ WETTENY JOSEPH
Wetteny Joseph
Executive Vice President and
Chief Financial Officer


Zoetis Inc

NYSE:ZTS

ZTS Rankings

ZTS Latest News

ZTS Latest SEC Filings

ZTS Stock Data

63.97B
442.76M
0.09%
98.66%
1.75%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
PARSIPPANY